On Aug.29,2011, Shandong Xinhua Pharmacuetical Co., Ltd. (“Shandong Xinhua”), one of the key pharmaceutical manufacture bases in China, was issued cGMP Certificate by UK MHRA for its solid dosage plant located in Zibo, Shandong. The GMP certification by UK MHRA means Shandong Xinhua is eligible to manufacture and export the solid dosage products to EU market.
    Established in 1943, as one of the national largest manufacturing and exporting bases in the chemical synthetic pharmaceuticals field, Shandong Xinhua is in an leading position in the manufacturing technology and capacity for antipyretics and analgesics in China and is an important manufacturer in China for the drugs for central nervous system, steroids, cardio and cerebrovascular system. Currently, 7 APIs have been site approved by US FDA, 10 APIs have been approved by EDQM. With the high commitment to the product quality and development of the international markets, Shandong Xinhua has established the strategic partnership with dozens of MNCs, the products of the Company has been distributed to more than 60 countries and regions.